Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use

Detalles Bibliográficos
Autores principales: DELEURAN, Mette, MARCOUX, Danielle, DE BRUIN-WELLER, Marjolein S., IRVINE, Alan D., BASELGA, Eulalia, AHN, Kangmo, CASTRO, Ana Paula, BANSAL, Ashish, CHAO, Jingdong, BÉGO-LE BAGOUSSE, Gaëlle, ROSSI, Ana B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society for Publication of Acta Dermato-Venereologica 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413654/
https://www.ncbi.nlm.nih.gov/pubmed/34043020
http://dx.doi.org/10.2340/00015555-3848

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413654/
https://www.ncbi.nlm.nih.gov/pubmed/34043020
http://dx.doi.org/10.2340/00015555-3848

Ejemplares similares